Výsledky vyhledávání - "Souzana Delibasi"

VAD-doxil versus VAD-doxil plus thalidomide as initial treatment for multiple myeloma: results of a multicenter randomized trial of the Greek myeloma study group

Autor: Konstantinos Zervas, Alice Maniatis, E. Terpos, C. Mitsouli, Meletios A. Dimopoulos, Souzana Delibasi, Marie-Christine Kyrtsonis, A. Anagnostopoulos, N. Anagnostopoulos, D Mihou, Eirini Katodritou, P Zikos, Anastasia Pouli

Publikováno v: Annals of Oncology. 18:1369-1375

Background: We have previously demonstrated that vincristine, liposomal doxorubicin and dexamethasone (VAD-doxil) is equally effective with VAD-bolus yielding objective response rates of 61% as first-line treatment in multiple myeloma (MM). In a phas

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a1bd70dbde8e4fa1da4c1fcbeed19a0a
https://doi.org/10.1093/annonc/mdm178

Zobrazit plný text záznamu

Primary treatment with pulsed melphalan, dexamethasone and thalidomide for elderly symptomatic patients with multiple myeloma

Autor: Meletios A, Dimopoulos, Athanasios, Anagnostopoulos, Evangelos, Terpos, Panagiotis, Repoussis, Athanasios, Zomas, Eirini, Katodritou, Marie Christine, Kyrtsonis, Souzana, Delibasi, Amalia, Vassou, Anastasia, Pouli, Konstantinos, Zervas, Nikolaos, Anagnostopoulos, Alice, Maniatis

Publikováno v: Haematologica. 91(2)

Fifty patients with multiple myelomaor=75 years of age received primary treatment with melphalan (M) 8 mg/m(2) on days 1-4, dexamethasone (D) 12 mg/m2 on days 1-4 and 17-20 and thalidomide (T) 300 mg at bedtime on days 1-4 and 17-20. This regimen was

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::147285035b1401bcfb23f927e2c3a84c
https://pubmed.ncbi.nlm.nih.gov/16461313

Zobrazit plný text záznamu

Primary Treatment with Pulsed Melphalan, Dexamethasone, Thalidomide (MDT) for Symptomatic Patients with Multiple Myeloma ≥ 75 Years of Age

Autor: Panagiotis Repoussis, Eirini Katodritou, Anastasia Pouli, Athanasios Anagnostopoulos, Amalia Vassou, Dimitrios Margaritis, Athanasios Zomas, Maria Christina Kyrtsonis, Evangelos Terpos, Meletios A. Dimopoulos, Souzana Delibasi, Nikolaos Anagnostopoulos, Alice Maniatis, Konstantinos Zervas

Publikováno v: Blood. 104:1482-1482

Introduction: Thalidomide is usually administered orally continuously once daily and has shown remarkable activity in about 30% of patients with heavily pretreated multiple myeloma (MM). Moreover, there is considerable interest in the administration

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ec3f5d935447bf199bab52ff881efcf7
https://doi.org/10.1182/blood.v104.11.1482.1482

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání